Last reviewed · How we verify

NCT06243120

Intravenous Lidocaine for Treating Intrathecal Fentanyl Induced Pruritus

Status unknown EARLY_PHASE1 Last updated 6 February 2024
What this trial tests

EARLY_PHASE1 trial testing Lidocaine IV in Pruritus Caused by Drug in 54 participants. Status unknown.

Timeline
1 March 2024
Primary endpoint
1 September 2024
1 October 2024

Quick facts

Lead sponsorAin Shams University
PhaseEARLY_PHASE1
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposetreatment
Enrollment54
Start date1 March 2024
Primary completion1 September 2024
Estimated completion1 October 2024
Sites1 location across Egypt

Drugs / interventions tested

Conditions studied

Sponsor

Ain Shams University

Who can join

Adults 18 to 70, any sex, with Pruritus Caused by Drug. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study will assess efficacy of intravenous lidocaine 1 mg/kg diluted with 0.9% sodium chloride to a volume of 100 ml to suppress intrathecal fentanyl induced pruritus. This will be compared to control group who will receive 100 ml normal saline as placebo. The main outcome is regression of initial VAS score with incidence of pruritus.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Lidocaine IV

Trials testing the same drug.

Other recruiting trials for Pruritus Caused by Drug

Currently open trials in the same condition.

Other Ain Shams University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06243120.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing